Barry Weed, MD
Psychiatry · Durham, NCNPI 1568534485
Payments from drug & device makers
Across 504 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$3K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$921
- Otsuka America Pharmaceutical, Inc.$916
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$687
- Johnson & Johnson$621
- plus $2K from 18 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$9,42796%
- Education$3834%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 144 | $2,994 |
| Alkermes, Inc. | 63 | $1,218 |
| Teva Pharmaceuticals USA, Inc. | 51 | $921 |
| Otsuka America Pharmaceutical, Inc. | 40 | $916 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 47 | $687 |
| Johnson & Johnson | 25 | $621 |
| AbbVie(2 entities) | 42 | $533 |
| Lundbeck LLC | 19 | $337 |
| Neurocrine Biosciences, Inc. | 13 | $331 |
| Avanir Pharmaceuticals, Inc. | 8 | $233 |
| Supernus Pharmaceuticals, Inc. | 6 | $199 |
| Indivior Inc. | 12 | $166 |
| Corium, LLC | 5 | $148 |
| Vanda Pharmaceuticals Inc. | 7 | $118 |
| Shire North American Group Inc | 5 | $84 |
| E.r. Squibb & Sons, L.L.C. | 3 | $78 |
| Almatica Pharma LLC | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Ironshore Pharmaceuticals Inc. | 2 | $36 |
| Orexo US, Inc. | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Brainsway USA Inc | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| MDD US Operations, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$464
- SPRAVATO$249
- ABILIFY MAINTENA$125
- NUEDEXTA$125
- INGREZZA$122
- LATUDA$119
- ARISTADA INITIO$116
How this compares
$9,810 in reported general payments places this provider in the 90th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 13 | $104,584 |
| Invega SustennaPaliperidone Palmitate | 40 | $96,131 |
| VraylarCariprazine Hcl | 43 | $64,012 |
| Abilify MaintenaAripiprazole | 21 | $58,450 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 200 | $50,810 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 61 | $45,532 |
| SpravatoEsketamine Hcl | 26 | $44,120 |
| FanaptIloperidone | 15 | $34,466 |
| CaplytaLumateperone Tosylate | 11 | $21,159 |
| Lurasidone Hcl | 170 | $19,473 |
| BelsomraSuvorexant | 34 | $16,570 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $16,091 |
| Buprenorphine Hcl | 182 | $11,331 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $11,285 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $8,524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Spravato | $621 | $244,83579 claims |
| AbbVieVraylar, Viibryd | $533 | $71,34065 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $916 | $58,45021 claims |
| Indivior Inc.Suboxone | $166 | $45,53261 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $118 | $34,46615 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $687 | $21,15911 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $50 | $16,09123 claims |
| Orexo US, Inc.Zubsolv | $26 | $11,28513 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $233 | $8,52411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Durham
- Mark ReynoldsDurham$3.2M
- Dan BlazerDurham$1M
- Andrew KrystalDurham$754K
- Rachel DewDurham$520K
- Steven SzaboDurham$412K
- Ranjan SudanDurham$303K
- Mustafa HusainDurham$156K
- Paolo MannelliDurham$98K
- Mark ChandlerDurham$86K
- Caleb WhitenackDurham$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.